As readers will know I was a big fan of AIM-listed biotech Scancell (SCLP) but lost my patience with what appeared to be an attempt to jump on the Covid bandwagon. Well blow me down, for today the shares have doubled to 28.25p at peak this morning. What’s going on (apart from me looking like a prize chump)?
There was bad news this morning from AIM-listed cancer-buster Scancell (SCLP): Cancer Research UK has pulled out of a funding deal to put Scancell’s second SCIB product through Phase I/II trials.
I have documented over many years what a rotten investment Scancell (SCLP) has been but its spoofing on its quest for a Covid vaccine is one of the biggest red flags fluttering. Today it plunged new depths of spoofery as it announced a collaboration with Cobra Biologics “for Cobra to manufacture Scancell's COVID-19 vaccine.” Great, except that…
Having previously bravely (or perhaps stupidly) held on to my bullish beliefs in AIM-listed Scancell (SCLP), I finally threw in the towel last week after what appeared to be an attempted ramp by jumping on the Covid-19 bandwagon. I said sell – and it appears it was not just me looking to get out...
One of my first ever tips for ShareProphets was AIM-listed Scancell (SCLP), way back in the 2015 New Year tipfest. It has not covered me in glory, having tipped it when it was hanging around the 23-33p mark as the shares closed last night at around 5p. I had hoped that it would turn itself around and its biotech business would find a willing buyer in the end. But today the shares are up buy a thumping 46% (last seen) on news of Development of vaccine against Covid-19. Should I be celebrating? I’m not so sure….
Pharmaceuticals isn’t a sector that I generally tend to invest in, other than possibly for the dividends paid by some of the huge multinational companies.
AIM-listed immunotherapy cancer specialist Scancell (SCLP) announced last week that the FDA had posed a few questions regarding its application to run a Phase II combination trial for its SCIB-1 skin cancer compound alongside a checkpoint inhibitor. The market saw this as bad news, and marked the shares down heavily – but I’m not so sure it is all that serious.
